Keeping in line with its strategy of balanced expansion
through all the segments, recently medical device major
Boston Scientific Corp
) came up with research and education funding of over $1 million
for its women's health segment. The company provided this grant
to the Pelvic Floor Disorders Network (PFDN) for the SUPeR
clinical trial which will evaluate the outcomes of two different
surgical options for women with uterine prolapse.
Uterine prolapse is a form of female genital prolapse. It is
also known as pelvic organ prolapse. This occurs when the tissue
and muscles of the pelvic floor fail to support the pelvic
organs, resulting in internal sagging or drooping of organs such
as the bladder, uterus or rectum.
Currently this market is growing handsomely with almost 28
million women in the US living with at least one pelvic floor
disorder. Apart from pelvic organ prolapse, the other most common
form of this disorder is urinary incontinence, the inability to
According to Boston scientific, in the SUPeR study there will
be enrollments of 180 women who opt for uterine prolapse surgery
and have no further plans to bear children. These patients
will be randomly assigned either a uterine-preserving
transvaginal mesh repair using the Boston Scientific Uphold LITE
Vaginal Support System or traditional surgery which includes a
Post-surgery, patients will be evaluated every six months for
another five years to determine surgical success. The
company expects the data to be available in 2017 and the final
outcome in another one year.
The Urology/Women's Health segment (presently contributing 7%
of total revenues) of Boston Scientific develops and manufactures
devices to treat various urological and gynecological disorders.
During the first quarter of 2013, the worldwide net sales of
these products were $118 million, down approximately 2% on a year
over year basis (up 1% at constant exchange rate or CER).
In spite of several product launches during the quarter with
growth in the international market, this division reported a
disappointing quarter due to declines in the Women's Health
Net sales from the Women's Health business declined 7% in the
last reported quarter primarily due to continued pressures on
elective procedures in the U.S. and lower U.S. sales following
the FDA release of a Public Health Notice update in July 2011
regarding complications related to the use of urogynecologic
surgical mesh for pelvic organ prolapse.
However, the company is still optimistic about this business
as it believes this division has the growth opportunity with
respect to recent product launches in the U.S. and continued
expansion of the global footprint.
Boston Scientific currently carries a Zacks Rank #3 (Hold).
Other medical sector stocks that warrant a look are
BOSTON SCIENTIF (BSX): Free Stock Analysis
CONCEPTUS INC (CPTS): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
HAEMONETICS CP (HAE): Free Stock Analysis
To read this article on Zacks.com click here.